Dec 30, 2022 | Blog, Case Study, CenExel, CenExel CNS, Clinical Trial
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of... 
Dec 28, 2022 | Blog, CenExel CNS, Psychiatry
We congratulate Brett A. English, PharmD, PhD VP, Clinical Sciences and Development CenExel, on his textbook chapter on cholinergic neurotransmission in the autonomic nervous system, published in The Primer on the Autonomic Nervous System – 4th Edition. This... 
Nov 3, 2022 | Blog, CenExel, CenExel HRI, Medical Specialties, Neurology, News, Pain Management
After decades of prohibition, psychedelic research has entered a renaissance within the scientific community. Once associated with hippie counterculture in the 60s and 70s, psychedelics are now receiving the reverence and critical consideration long sought by...Oct 31, 2022 | Blog, Case Study, CenExel, CenExel HRI, News, Placebo Study
Elan Cohen, Ph.D., Principal Investigator, CenExel HRI The pervasive placebo effect observed within clinical trials, where drug and placebo demonstrate “comparable efficacy,” continues to have significance, with the slightly over 50% failure rate in the...
Recent Comments